For the readers interested in the stock health of Freeline Therapeutics Holdings plc (FRLN). It is currently valued at $0.62. When the transactions were called off in the previous session, Stock hit the highs of $0.68, after setting-off with the price of $0.58. Company’s stock value dipped to $0.5756 during the trading on the day. When the trading was stopped its value was $0.55.Recently in News on January 19, 2023, Freeline Publishes Preclinical Proof-of-Concept Data for FLT190, its AAV Gene Therapy Candidate for Fabry Disease, in the Nature Journal Gene Therapy. Data show increased enzyme activity and reduction of harmful substrate, an established biomarker of efficacy in Fabry disease, in key tissues and organs. You can read further details here
Freeline Therapeutics Holdings plc had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $0.6800 on 01/23/23, with the lowest value was $0.4613 for the same time period, recorded on 01/03/23.
Freeline Therapeutics Holdings plc (FRLN) full year performance was -56.30%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Freeline Therapeutics Holdings plc shares are logging -55.99% during the 52-week period from high price, and 33.96% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.46 and $1.40.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 643394 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Freeline Therapeutics Holdings plc (FRLN) recorded performance in the market was 29.70%, having the revenues showcasing -9.38% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 36.41M, as it employees total of 235 workers.
Analysts verdict on Freeline Therapeutics Holdings plc (FRLN)
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 0.6577, with a change in the price was noted -0.21. In a similar fashion, Freeline Therapeutics Holdings plc posted a movement of -25.76% for the period of last 100 days, recording 43,911 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for FRLN is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Freeline Therapeutics Holdings plc (FRLN): Technical Analysis
Raw Stochastic average of Freeline Therapeutics Holdings plc in the period of last 50 days is set at 54.96%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 71.00%. In the last 20 days, the company’s Stochastic %K was 54.06% and its Stochastic %D was recorded 44.92%.
Let’s take a glance in the erstwhile performances of Freeline Therapeutics Holdings plc, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 29.70%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -23.98%, alongside a downfall of -56.30% for the period of the last 12 months. The shares increased approximately by 18.50% in the 7-day charts and went down by 18.52% in the period of the last 30 days. Common stock shares were lifted by -9.38% during last recorded quarter.